News
Public · Published
AbbVie in Charts: Skyrizi and Rinvoq continue double-digit Y/Y expansion in Q3 '26; Humira falls 31%
AbbVie's Q3 '26 results show its drugs Skyrizi and Rinvoq continued to grow at double-digit rates compared with the same period a year earlier, while sales of its older drug Humira fell 31%.
Published:
Updated:
What happened
AbbVie's Q3 '26 results show its drugs Skyrizi and Rinvoq continued to grow at double-digit rates compared with the same period a year earlier, while sales of its older drug Humira fell 31%.
Confirmed
Global impact / market context
AbbVie is replacing falling Humira revenue with newer drugs. If Skyrizi and Rinvoq keep growing at double-digit rates, they can offset Humira's decline, supporting total revenue and cash available to fund research, dividends, and debt reduction.
Analyst inference
Investors watch whether newer drugs grow fast enough to replace older ones losing sales. Double-digit growth in Skyrizi and Rinvoq against a 31% Humira drop suggests the shift is working, but the article gives no total revenue figures or investor reaction.
Analyst inference
What to watch
- Watch whether Skyrizi and Rinvoq keep growing at double-digit yearly rates, since that pace is what offsets Humira's 31% sales decline. Confirmed
- Watch for future company disclosures on total revenue and profit per sale, to see if newer drugs fully replace Humira's lost sales. Proposed
- Watch Humira's decline rate; a steeper fall could pressure total revenue and cash available if the newer drugs' growth slows at the same time. Analyst inference